CD274 and neoplasm: Although PD-L1 and the tumor mutation burden (TMB) are known to be predictive biomarkers of the response to ICIs, given that their predictive ability is limited in clinical practice [4], other biomarkers of the response to ICIs and the association between those biomarkers and the TMB must be explored to optimize treatment for patients with NSCLC.